The use of palliative care programs and the number of trials assessing their effectiveness have increased.
Study Eligibility
Two reviewers (D.K. and L.H.) independently evaluated all records for eligibility (eTable 1 in the Supplement). Disagreements were resolved by consensus with 2 other authors (J.C. and Y.S.). The RCTs investigating palliative care interventions targeting adult patients (≥18 years) with life-threatening illness that reported on at least 1 of 9 patient-level outcomes were included: QOL, symptom burden, mood, survival, advance care planning, site of death, resource utilization, health care expenditures, and satisfaction with care. Interventions were included if they comprised at least 2 of 8 possible domains of palliative care, as defined by the National Consensus Project for Quality Palliative Care. 18 Interventions that treated a single symptom (eg, opioids for dyspnea), targeted only one palliative care domain (eg, advance care planning only), or did not target patients (eg, caregiver-only interventions) were excluded. Trials with usual care, waitlist, or attention control comparators were included.
Data Extraction and Risk of Bias Assessment
Two of 4 investigators (D.K., J.C., N.C.E., J.H.) used structured, customized forms to extract information from each trial's primary and secondary reports. Risk of bias was independently rated by 2 investigators (D.K., J.N.D-O.) using the Cochrane Collaboration's tool. 17 Within each trial, risk of bias was evaluated separately for subjective (eg, patientreported outcomes) and objective (eg, survival) outcomes. Therefore, each trial has 2 summary risk-of-bias judgments, 1 regarding subjective outcomes and 1 for objective outcomes. Detailed information regarding risk of bias assessment is provided in eText 2 in the Supplement. Trial authors were contacted to provide additional detail necessary to render high or low judgments.
Synthesis
A narrative synthesis was conducted for all trials. In addition, patient QOL, symptom burden, and survival outcomes were selected a priori for meta-analysis. Quality of life and symptom burden are considered to be primary targets of palliative care interventions. However, the association of palliative care and survival has been of considerable interest. 12, 19, 20 Due to the variety of instruments used to evaluate QOL and symptom burden, pooled effects were summarized as standardized mean differences (SMDs), calculated using a Hedges adjusted g estimator to correct for small sample bias. 21 If necessary, individual study results were corrected for directionality such that higher QOL scores represented better QOL, and lower symptom scores indicated less symptom burden. Pooled SMDs were reexpressed as units of familiar instruments by multiplying SMDs by the among-person SDs of the Functional Assessment of Chronic Illness Therapy-palliative care scale (FACIT-Pal) 22 for QOL, and the Edmonton Symptom Assessment Scale (ESAS) 23 for symptom burden (eText 3 in the Supplement). 24 Translations are provided to assist with interpretation of results; however, due to differences in study variances, inferences regarding statistical significance of findings should be interpreted from SMD calculations. The FACIT-Pal scores range from 0 (worst) to 184 (best). Although the minimal clinically important difference (MCID) is unknown for the FACIT-Pal, it has been suggested that MCIDs for total Functional Assessment of Cancer Therapy (FACT) scores, including the FACIT-Pal, are 4% to 6% of a measure's overall score. 25 A midrange bound of 5% equals 9 points on the FACIT-Pal. Edmonton Symptom
Key Points
Question Is palliative care associated with improved patient and caregiver outcomes?
Findings In this meta-analysis of randomized clinical trials, palliative care was associated with improvements in quality of life and symptom burden but not with improved survival. However, results were attenuated and some of these associations were no longer statistically significant when analyses were restricted to trials at low risk of bias.
Meaning Palliative care may be associated with improved quality of life and symptom burden for patients, but findings for caregiver outcomes were mixed. However, the quality of evidence is limited.
Given heterogeneity across trials, DerSimonian-Laird random effects models were constructed using Stata version 13 (StataCorp). All significance tests were 2-tailed, with P < .05 considered statistically significant. The proportion of variability in point estimates attributable to between-study heterogeneity was quantified by the I 2 statistic 21 and interpreted qualitatively as low (25%-50%), moderate (50%-75%), and high (75%-100%). 27 Heterogeneity was also examined using τ 2 and
Cochrane Q statistics. All studies included in the metaanalysis had comparable baseline characteristics between intervention and control groups or outcome measurements adjusted by baseline scores.
To account for variability in the timing of study end points, clinically relevant follow-up periods of 1 to 3 and 4 to 6 months were used. For studies that reported outcomes at more than one time point within the same 1-to 3-or 4-to 6-month window, the last time point was analyzed. Outcomes reported between 2 time points were categorized with the earlier month. Hazard ratios (HRs) were used as the treatment effect for survival. Hazard ratios were imputed when they were not provided using the log-rank approach. 28, 29 Sensitivity analyses were conducted to evaluate the influence of risk of bias, the use of follow-up time windows (vs 3-or 6-month discrete follow-up time points), and imputation of HRs. Post hoc analyses were conducted to assess whether associations varied according to setting and disease (cancer only, noncancer only, or mixed-disease samples). Univariable meta-regression was used to explore associations between estimated effect sizes and publication year and intervention intensity. Publication bias was assessed through funnel plots and Egger tests. Statistical heterogeneity was explored by modeling study-level characteristics using univariable meta-regression.
Results

Study Characteristics
Searches identified 6158 unique records, of which 200 were potentially relevant based on initial screening (Figure 1) . Fiftysix articles were ultimately included, describing 43 trials that involved 12 731 patients (mean age, 67 years) and 2479 caregivers (eTables 2-4 in the Supplement). Thirty trials (69.7%) included patients with cancer and 14 trials (32.5%) included patients with heart failure, both of which diseases represent the diagnoses most commonly requiring palliative care. Thirtyone trials (72.0%) were conducted in the United States. Fourteen trials (32.5%) were in ambulatory settings; 18 (41.8%), home-based; and 11 (25 
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Thirty-nine studies used parallel-group designs (35 with a usual-care comparator, 2 with active comparators, and 2 with attention controls). Five studies used waitlist designs, 20, 43, [45] [46] [47] with delay intervals ranging from 2 to 12 weeks. Most trials randomized patients; 5 used cluster randomization. Fifteen trials evaluating QOL at the 1-to 3-month follow-up could be pooled in meta-analysis; of these, 11 exclusively comprised patients with cancer, and 8 used ambulatory interventions. Among these 15 trials, palliative care was associated with statistically significant and clinically meaningful improvement in QOL at 1 to 3 months (SMD, 0.46; 95% CI, 0.08 to 0.83; Figure 2 ; mean difference in FACIT-Pal units, 11.36; heterogeneity, I 2 = 94.8%). There was no association of palliative care
and QOL among 12 trials pooled with 4-to 6-month follow-up ( Figure 3 ). In sensitivity analyses restricted to trials at low risk of bias, palliative care was associated with improved QOL at the 1-to 3-month follow-up, but the point estimate was attenuated (SMD, 0.20; 95% CI, 0.06-0.34; 5 trials; I 2 = 0.0%; Ten trials involving 1813 participants were pooled in a metaanalysis regarding symptom burden at the 1-to 3-month follow-up [8] [9] [10] 12, 20, 43, 46, 54, 57, 60 ; 4 trials were judged as having a low risk, 8, 12 ,57,60 1 as unclear, 46 and 5 as high risk of bias. 9, 10, 20, 43, 54 Palliative care was associated with a statistically and clinically significant reduction in symptom burden at the 1-to 3-month follow-up, but the analysis had extremely high heterogeneity (SMD, −0.66; 95% CI, −1.25 to −0.07; I 2 = 96.1%; Figure 4 ; mean difference in ESAS units, −10.30). At the 4-to 6-month follow-up, palliative care was associated with improved symptom burden (SMD, −0.18; 95% CI, −0.31 to −0.05; I 2 = 0.0%; Figure 5 ; mean difference in ESAS units, −2.80).
In sensitivity analyses limited to the 4 trials at low risk of bias, palliative care was not associated with change in symptom burden at the 1-to 3-month follow-up (SMD, −0.21; 95% CI, −0.42 to 0.00; I 2 = 42.1%; Figure 4 ; mean difference in ESAS units, −3.28; 4 trials). Nor was it associated with change in symptom burden at the 4-to 6-month follow-up (SMD, −0.13; 95% CI, −0.27 to 0.01; I 2 = 0.0%; Figure 5 ; mean difference in ESAS units, −2.03, 4 trials). Additional post hoc analyses related to disease, setting, or discrete time point assessment revealed no associations between palliative care and symptom burden (eFigures 7-9). There was no evidence of publication bias (eFigure 10). Heterogeneity was largely explained by study setting, with e Cancer, COPD, heart failure, interstitial lung disease, motor neuron disease.
f Non-small cell lung cancer.
g Lung, gastrointestinal, genitourinary, breast, and gynecological cancers.
Survival
Survival was assessed in 17 trials involving 8196 patients; 10 trials were judged as having high risk of bias, 9, 20, 34, 39, 49, 52, 55, 60, 67, 68 5 as unclear risk, 11, 13, 50, 65, 66 and 2 as low risk. 12,57 One trial specified survival as a primary outcome. 20 The 2 trials at low risk of bias reported conflicting findings. A telepalliative care intervention for patients with advanced cancer reported no effect on survival (HR, 0.82; 95% CI, 0.64-1.07), 20 whereas a trial of integrated palliative and respiratory care for dyspnea, which included survival as a safety outcome, reported greater survival at 6 months (94% vs 75%, P = .048). 12 Three additional trials (2 at high risk of bias, 20 ,60 1 at unclear risk 13 ) reported statistically significant improvements in survival.
Seven trials involving 2184 patients that assessed survival were pooled in a meta-analysis. 9, 11, 13, 50, 57, 60, 65 One trial was rated as having low risk of bias, summarized above.
12
There was no association between palliative care and survival (HR, 0.90; 95% CI, 0.69-1.17; I 2 = 75.3%; Figure 6 ). Post hoc analyses related to disease, setting, or imputation of HRs identified no significant associations of palliative care and survival (eFigures [11] [12] [13] . No evidence of publication bias was detected (eFigure 14). Heterogeneity of estimates could not be explained by study-level characteristics (eTable 7 in the Supplement).
Patient Mood
There was mixed evidence from 23 trials involving 4175 patients regarding the association of palliative care with mood. Of the 23 trials, 13 were judged as high risk, ; of these, 4 were at low risk of bias.
57-60 Of the 5 trials at low risk of bias, 12,57-60 4 reported statistically significant improvements in mood.
57-60
Advance Care Planning For all trials, the P value for the pooled hazard ratio (HR) was .44; τ 2 , 0.08; and Q, 24.29. For trials at low risk of bias, the P value for the pooled the HR was .14; τ 2 , <0.0001; and for Q, <0.0001. For high risk of bias, the P value for the pooled HR was .99; τ ; of these, 11 reported significantly decreased utilization among palliative care recipients. 10, 34, 37, 38, 48, 50, 52, 65, 66, 71, 73 Hospital utilization was assessed in 20 trials involving 4329 patients; of these, 11 trials were judged as having high risk of bias, 9, 10, 20, 34 ; of these, 4 were judged at high risk of bias, 10,34,52,67 and 1 at unclear risk. 71 Six trials involving 1360 patients assessed hospice use; of these, 3 trials were judged as having high risk of bias 9,55,68 and 3 as unclear risk. 11, 65, 71 Overall, 1 trial involving 517 participants and judged as having an unclear risk of bias that assessed inpatient specialist palliative care consultation reported significantly longer hospice stays among intervention patients (median, 24 vs 12 days; P = .04), although the overall percentage of patients admitted to hospice did not differ between groups (P = .50). 65 Four trials involving 704 patients evaluated the use of intensive nonpalliative services (eg, chemotherapy within the last 14 days of life, no hospice care, or admission to hospice ≤3 days before death), of which 1 trial was judged as having high risk of bias, 20 2 as unclear risk, 37,66 and 1 as low risk. 60 The trial at low risk reported no association between palliative care and intensive, nonpalliative services (P = .05).
60
Twelve trials involving 6892 patients assessed health care expenditures; of these 7 trials were judged as having high risk of bias, 34,39,43,47- 30, 32, 33 reported benefit in at least 1 domain at 1 or more time points, although only 1 was at low risk of bias. 33 Caregiver satisfaction was measured in 5 studies. Of these, 34, [37] [38] [39] 42 four 34, [37] [38] [39] showed higher scores among intervention groups; however, 3 were at high risk of bias 34, 38, 39 and 1 was at unclear risk. 37 
Discussion
In this meta-analysis, palliative care interventions were associated with significant improvements in QOL and symptom burden but not in 1-to 3-month survival. However, because of marked heterogeneity among trials in methodological quality and rigor, there was weak evidence for these associations. When sensitivity analyses were restricted to trials at low risk of bias, associations between palliative care and QOL remained statistically significant but not clinically important and associations with symptom burden were no longer statistically significant. Of the outcomes narratively synthesized, palliative care was associated with improved advance care planning, greater patient and caregiver satisfaction with care, and lower health care utilization. There was mixed evidence of associations of palliative care with site of death; patient mood; health care expenditures; and caregiver QOL, mood, or burden. This study adds to the literature by (1) including 23 trials published since a 2008 systematic review 6 and 29 trials not included in the 2011 narrative review, 7 (2) by evaluating risks of bias and methodological limitations in each trial, and (3) by conducting a systematic review that includes a meta-analysis of 3 important outcomes. Although these analyses provide increased evidence for the association of palliative care with several patient and caregiver outcomes, particularly for patients with advanced cancer, the results should be interpreted cautiously given persistent methodological limitations. Highquality palliative care studies with innovative and contextspecific methods are needed that are responsive to the complexities of conducting research in seriously ill populations are needed. 74, 75 Although all included trials involved patients with lifelimiting illness, there was wide variability across samples. This is consistent with the concept that palliative care is appropriate at any stage of life-limiting illness, including patients less severely ill. 2 However, the effects of palliative care may be more difficult to demonstrate among people with less symptom burden or QOL impairment. Future meta-analyses should account for this diversity between studies, to avoid ceiling and floor effects. Survival was reported as an outcome in recent trials, although improving survival is not an aim of palliative care. 2 Only one trial specified survival as a primary end point. 20 Given that some clinicians and members of the lay public view palliative crease in survival from palliative care. The association of palliative care with caregiver outcomes was mixed. Three explanations may clarify these seemingly discrepant findings. First, many of the reviewed interventions did not specifically target caregivers. Included trials were typically patient focused. Second, of palliative care interventions that targeted caregivers, there was considerable variability in their type and delivery. Third, care needs of patients with life-limiting illness change as patient health deteriorates. Hence, despite training in coping skills, caregivers may feel burdened by having to adapt to these changing needs. Because we excluded caregiver-focused interventions, the outcomes presented reflect only caregiver outcomes of patientfocused palliative care interventions.
Strengths and Weaknesses
This review used a broad search for palliative care RCTs to detect interventions consistent with the philosophy or components of palliative care, including interventions that may not be explicitly described as palliative care. Consequently, this review includes a wide spectrum of palliative care delivery models, with interventions ranging from interdisciplinary specialized palliative care to those in which palliative care domains were delivered by a nonpalliative care specialist. Although all interventions met our prespecified definition of "palliative care," their diversity likely introduced heterogeneity into the meta-analysis. 78 The use of a random-effects model measures variability between trials, weighting each study's contribution within the pooled effect. This review regards palliative care as a philosophy of care. Insufficient data were available to identify the associations between specific models of palliative care (eg, specialist vs generalist palliative care training) and patient and caregiver outcomes. This review has several limitations. First, several trials could not be included in meta-analyses, typically, because missing data remained even after contacting authors. Second, the review excluded quasi-experimental studies, several of which have demonstrated benefits of palliative care. 79, 80 Third, post hoc analyses including meta-regressions and tests for publication bias should be interpreted cautiously given that these statistical tests may have been underpowered. Fourth, trial duration and attrition rates were not uniformly reported in studies and are therefore excluded from this review. Fifth, this review did not distinguish between early palliative care interventions vs those at the end-of-life, reflecting the prevailing view that palliative care is appropriate at any point in the disease trajectory. 2 Sixth, risk of bias assessment is subjective, and the Cochrane Risk of Bias tool is not designed to account for the intricacies of conducting behavioral interventions among seriously ill populations. Given these limitations, results of this systematic review and meta-analysis should be interpreted cautiously.
Unanswered Questions and Future Research
Several gaps remain regarding palliative care. First, this review could not discern the association between specific palliative care processes and outcomes. Future research should aim to identify the efficacious component(s) of palliative care. Second, future studies should assess patient-reported outcomes using a core set of standardized and validated measures appropriate for seriously ill patients at similar time points. Third, additional studies are needed to evaluate the role of palliative care in chronic nonmalignant illnesses (eg, heart failure, chronic obstructive pulmonary disease, renal disease). Fourth, among subgroups for which the efficacy of palliative care has been established (eg, oncology), future trials should consider active controls to investigate the comparative effectiveness of different palliative care strategies. Finally, trials are needed to establish optimal models of palliative care delivery that help caregivers in addition to patients.
Conclusions
In this meta-analysis, palliative care interventions were associated with improvements in patient QOL and symptom burden. Findings for caregiver outcomes were inconsistent. However, many associations were no longer significant when limited to trials at low risk of bias, and there was no significant association between palliative care and survival.
